<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35450781</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>22</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine.</ArticleTitle><Pagination><StartPage>3072</StartPage><EndPage>3084</EndPage><MedlinePgn>3072-3084</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.04.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00418-2</ELocationID><Abstract><AbstractText>Uncertainty surrounding the risk of developing and dying from Thrombosis and Thrombocytopenia Syndrome (TTS) associated with the AstraZeneca (AZ) COVID-19 vaccine may contribute to vaccine hesitancy. A model is urgently needed to combine and effectively communicate evidence on the risks versus benefits of the AZ vaccine. We developed a Bayesian network to consolidate evidence on risks and benefits of the AZ vaccine, and parameterised the model using data from a range of empirical studies, government reports, and expert advisory groups. Expert judgement was used to interpret the available evidence and determine the model structure, relevant variables, data for inclusion, and how these data were used to inform the model. The model can be used as a decision-support tool to generate scenarios based on age, sex, virus variant and community transmission rates, making it useful for individuals, clinicians, and researchers to assess the chances of different health outcomes. Model outputs include the risk of dying from TTS following the AZ COVID-19 vaccine, the risk of dying from COVID-19 or COVID-19-associated atypical severe blood clots under different scenarios. Although the model is focused on Australia, it can be adapted to international settings by re-parameterising it with local data. This paper provides detailed description of the model-building methodology, which can be used to expand the scope of the model to include other COVID-19 vaccines, booster doses, comorbidities and other health outcomes (e.g., long COVID) to ensure the model remains relevant in the face of constantly changing discussion on risks versus benefits of COVID-19 vaccination.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mayfield</LastName><ForeName>Helen J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Electronic address: h.mayfield@uq.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Colleen L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinclair</LastName><ForeName>Jane E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Samuel J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baird</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>St Kilda Medical Group, St Kilda, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litt</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Discipline of General Practice, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia; Scientific Advisory Committee, Immunisation Coalition, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vuorinen</LastName><ForeName>Aapeli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Data Science Institute, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Short</LastName><ForeName>Kirsty R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waller</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mengersen</LastName><ForeName>Kerrie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Mathematical Sciences, Faculty of Science, Queensland University of Technology, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>B5S3K2V0G8</RegistryNumber><NameOfSubstance UI="D000090985">ChAdOx1 nCoV-19</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090985" MajorTopicYN="N">ChAdOx1 nCoV-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse events</Keyword><Keyword MajorTopicYN="N">Bayesian network</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Informed decision-making</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35450781</ArticleId><ArticleId IdType="pmc">PMC8989774</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.04.004</ArticleId><ArticleId IdType="pii">S0264-410X(22)00418-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Leask J., Carlson S.J., Attwell K., Clark K.K., Kaufman J., Hughes C., et al. Communicating with patients and the public about COVID-19 vaccine safety: recommendations from the Collaboration on Social Science and Immunisation. Med J Aust. 2021;215(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8361917</ArticleId><ArticleId IdType="pubmed">34137034</ArticleId></ArticleIdList></Reference><Reference><Citation>MacIntyre C.R., Veness B., Berger D., Hamad N., Bari N. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people &lt; 60 years in Australia. Vaccine. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270740</ArticleId><ArticleId IdType="pubmed">34272095</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenton N., Neil M. CRC Press; New York: 2013. Risk assessment and decision analysis with Bayesian networks.</Citation></Reference><Reference><Citation>Fenton N.E., McLachlan S., Lucas P., Dube K., Hitman G.A., Osman M., et al. A Bayesian network model for personalised COVID19 risk assessment and contact tracing. medRxiv. 2021 p. 2020.07.15.20154286.</Citation></Reference><Reference><Citation>Marcot B.G. Common quandaries and their practical solutions in Bayesian network modeling. Ecol Model. 2017;358:1&#x2013;9.</Citation></Reference><Reference><Citation>Uusitalo L. Advantages and challenges of Bayesian networks in environmental modelling. Ecol Model. 2007;203(3&#x2013;4):312&#x2013;318.</Citation></Reference><Reference><Citation>McLachlan S, Lucas PJ, Dube K, Hitman G, Osman M, Kyrimi E., et al. The fundamental limitations of COVID-19 contact tracing methods and how to resolve them with a Bayesian network approach; 2020.</Citation></Reference><Reference><Citation>Wu Y., Foley D., Ramsay J., Woodberry O., Mascaro S., Nicholson A.E., et al. Bridging the gaps in test interpretation of SARS-CoV-2 through Bayesian network modelling. Epidemiol Infect. 2021;149:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314199</ArticleId><ArticleId IdType="pubmed">34165071</ArticleId></ArticleIdList></Reference><Reference><Citation>Neil M., Fenton N., Osman M., McLachlan S. Bayesian network analysis of Covid-19 data reveals higher infection prevalence rates and lower fatality rates than widely reported. J Risk Res. 2020;23(7&#x2013;8):866&#x2013;879.</Citation></Reference><Reference><Citation>Immunisation Coalition. CoRiCal: Covid Risk Calculator. 2021 24 October 2021]; Available from: https://corical.immunisationcoalition.org.au.</Citation></Reference><Reference><Citation>Sinclair J.E., Mayfield H.J., Short K.R., Brown S.J., Puranik R., Mengersen K., et al. Quantifying the risks versus benefits of the Pfizer COVID-19 vaccine in Australia: a Bayesian network analysis. medRxiv. 2022 p. 2022.02.07.22270637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9371378</ArticleId><ArticleId IdType="pubmed">35953502</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticehurst J.L., Curtis A., Merritt W.S. Using Bayesian Networks to complement conventional analyses to explore landholder management of native vegetation. Environ Modell Software. 2011;26(1):52&#x2013;65.</Citation></Reference><Reference><Citation>Bayes Fusion. GeNIe Modeller available at https://www.bayesfusion.com/. 2019.</Citation></Reference><Reference><Citation>S&#xf8;gaard K.K., Darvalics B., Horv&#xe1;th-Puh&#xf3; E., S&#xf8;rensen H.T. Survival after splanchnic vein thrombosis: A 20-year nationwide cohort study. Thromb Res. 2016;141:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26945454</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageno W., Dentali F., Pomero F., Fenoglio L., Squizzato A., Pagani G., et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. Thromb Haemost. 2017;117(04):794&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">28180235</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristoffersen E.S., Harper C.E., Vetvik K.G., Zarnovicky S., Hansen J.M., Faiz K.W. Incidence and mortality of cerebral venous thrombosis in a norwegian population. Stroke. 2020;51(10):3023&#x2013;3029.</Citation><ArticleIdList><ArticleId IdType="pubmed">32883194</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Husain M., Geddes J., Luciano S., Harrison P. Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. Emedicine. 2021;39:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324974</ArticleId><ArticleId IdType="pubmed">34368663</ArticleId></ArticleIdList></Reference><Reference><Citation>ATAGI Australian Technical Advisory Group on Immunisation (ATAGI) weekly COVID-19 meeting on 8 September 2021 update; 2021.</Citation></Reference><Reference><Citation>NSW Government NSW COVID-19 cases data; 2021.</Citation></Reference><Reference><Citation>NNDSS National Notifiable Diseases Surveillance System public datasets; 2021.</Citation></Reference><Reference><Citation>Pitchforth J., Mengersen K. A proposed validation framework for expert elicited Bayesian Networks. Expert Syst Appl. 2013;40(1):162&#x2013;167.</Citation></Reference><Reference><Citation>Thabane L., Mbuagbaw L., Zhang S., Samaan Z., Marcucci M., Ye C., et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Method. 2013;13(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720188</ArticleId><ArticleId IdType="pubmed">23855337</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty Institute, Doherty modelling report revised 10th August 2021; 2021, Doherty Institute. p. Table S2.5.</Citation></Reference><Reference><Citation>Vaccine Effectiveness Expert Panel VEEP: Vaccine effectiveness table; 16 July 2021. 2021.</Citation></Reference><Reference><Citation>ATAGI, T. Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca; 2021.</Citation></Reference><Reference><Citation>Australian Bureau of Statistics. Data downloads - time series spreadsheets. National, state and territory population, 2021. 2021 01/10/2021]; Available from: https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2020#data-download.</Citation></Reference><Reference><Citation>Bayes Fusion. Sensitivity analysis in Bayesian networks (and influence diagrams). 2020 [cited 2022 28/03/22]; Available from: https://support.bayesfusion.com/docs/GeNIe/bn_sensitivitybn.html.</Citation></Reference><Reference><Citation>Lau C.L., Mayfield H.J., Sinclair J.E., Brown S.J., Waller M., Enjeti A.K., et al. Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework. Vaccine. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8566665</ArticleId><ArticleId IdType="pubmed">34810000</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards R., San&#xf3; M., Roiko A., Carter R.W., Bussey M., Matthews J., et al. Bayesian belief modeling of climate change impacts for informing regional adaptation options. Environ Modell Software. 2013;44:113&#x2013;121.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>